Published in Cochrane Database Syst Rev on December 08, 2010
Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J (2014) 1.74
Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. Clin Transl Allergy (2016) 1.42
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Immunotherapy in allergy and cellular tests: state of art. Hum Vaccin Immunother (2014) 0.98
Environmental assessment and exposure control of dust mites: a practice parameter. Ann Allergy Asthma Immunol (2013) 0.93
Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy (2014) 0.93
Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin Immunol (2013) 0.92
Allergen immunotherapy and allergic rhinitis: false beliefs. BMC Med (2013) 0.92
Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol (2013) 0.90
Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest (2012) 0.88
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy (2012) 0.87
International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ J (2017) 0.83
Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy (2014) 0.82
Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? Am J Rhinol Allergy (2012) 0.82
Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int (2013) 0.81
Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. Clin Exp Otorhinolaryngol (2014) 0.80
5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study. J Asthma Allergy (2013) 0.79
Optimal management of allergic rhinitis. Arch Dis Child (2015) 0.79
Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. Drug Des Devel Ther (2012) 0.78
Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. Eur Arch Otorhinolaryngol (2014) 0.78
Consensus Conference on Clinical Management of pediatric Atopic Dermatitis. Ital J Pediatr (2016) 0.78
A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clin Transl Allergy (2014) 0.78
Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg (2013) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ. Clin Exp Immunol (2014) 0.76
Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76
Is clinical tolerance possible after allergen immunotherapy? Curr Allergy Asthma Rep (2015) 0.76
A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia). Patient Prefer Adherence (2017) 0.75
Extracts from The Cochrane Library: Sublingual immunotherapy for allergic rhinitis. Otolaryngol Head Neck Surg (2011) 0.75
Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. Clinicoecon Outcomes Res (2012) 0.75
Evaluation of a sublingual immunotherapy solution in olive-induced respiratory allergy in Jordan: a retrospective observational study. J Asthma Allergy (2017) 0.75
Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials. Allergy Asthma Immunol Res (2017) 0.75
Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy. Curr Treat Options Allergy (2017) 0.75
Allergen immunotherapy: routes, safety, efficacy, and mode of action. Immunotargets Ther (2013) 0.75
Selling falsehoods? A cross-sectional study of Canadian naturopathy, homeopathy, chiropractic and acupuncture clinic website claims relating to allergy and asthma. BMJ Open (2016) 0.75
Allergen-specific immunotherapy in pediatric allergic asthma. Asia Pac Allergy (2016) 0.75
Oral mucosal immunotherapy for allergic rhinitis: A pilot study. Allergy Rhinol (Providence) (2016) 0.75
Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain. Clin Mol Allergy (2017) 0.75
House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy (2016) 0.75
Role of immunotherapy in the treatment of allergic asthma. World J Clin Cases (2014) 0.75
Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review. CMAJ Open (2017) 0.75
Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol (2016) 0.75
Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One (2017) 0.75
Control of chemokine-guided cell migration by ligand sequestration. Cell (2008) 4.61
Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol (2009) 3.91
Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol (2004) 3.49
Candida albicans pathogenicity mechanisms. Virulence (2013) 2.60
Cerebral microbleeds and postthrombolysis intracerebral hemorrhage risk Updated meta-analysis. Neurology (2015) 2.28
Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg (2004) 2.01
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol (2013) 1.96
Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol (2009) 1.77
The skin prick test - European standards. Clin Transl Allergy (2013) 1.60
From attachment to damage: defined genes of Candida albicans mediate adhesion, invasion and damage during interaction with oral epithelial cells. PLoS One (2011) 1.54
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Candida albicans iron acquisition within the host. FEMS Yeast Res (2009) 1.35
Candida albicans dimorphism as a therapeutic target. Expert Rev Anti Infect Ther (2012) 1.34
Candida albicans scavenges host zinc via Pra1 during endothelial invasion. PLoS Pathog (2012) 1.34
The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J Immunol (2011) 1.33
Systematic reviews of sublingual immunotherapy (SLIT). Allergy (2011) 1.25
Candida albicans-epithelial interactions: dissecting the roles of active penetration, induced endocytosis and host factors on the infection process. PLoS One (2012) 1.12
Efficacy of allergen-specific immunotherapy for patients with atopic dermatitis. J Allergy Clin Immunol (2013) 1.09
Are meta-analysis-based comparisons solid evidence? J Allergy Clin Immunol (2013) 1.09
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol (2013) 1.03
Regulatory network modelling of iron acquisition by a fungal pathogen in contact with epithelial cells. BMC Syst Biol (2010) 1.02
The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol (2008) 1.01
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Assessment of disease control in allergic rhinitis. Clin Transl Allergy (2013) 0.95
The novel Candida albicans transporter Dur31 Is a multi-stage pathogenicity factor. PLoS Pathog (2012) 0.95
Chemical genetics suggests a critical role for lysyl oxidase in zebrafish notochord morphogenesis. Mol Biosyst (2006) 0.95
Host-pathogen interactions and virulence-associated genes during Candida albicans oral infections. Int J Med Microbiol (2011) 0.94
Mechanisms of sublingual immunotherapy. J Asthma (2009) 0.93
Small but crucial: the novel small heat shock protein Hsp21 mediates stress adaptation and virulence in Candida albicans. PLoS One (2012) 0.93
Beta₂-agonists for exercise-induced asthma. Cochrane Database Syst Rev (2013) 0.92
Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev (2011) 0.91
Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole. Antimicrob Agents Chemother (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol (2012) 0.88
Chemokine and Fgf signalling act as opposing guidance cues in formation of the lateral line primordium. Development (2012) 0.87
Epithelial invasion outcompetes hypha development during Candida albicans infection as revealed by an image-based systems biology approach. Cytometry A (2013) 0.86
Does rhinitis lead to asthma? Rhinology (2007) 0.86
Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin (2010) 0.85
Military nutrition: maintaining health and rebuilding injured tissue. Philos Trans R Soc Lond B Biol Sci (2011) 0.81
Gene acquisition, duplication and metabolic specification: the evolution of fungal methylisocitrate lyases. Environ Microbiol (2011) 0.79
Methylcitrate cycle activation during adaptation of Fusarium solani and Fusarium verticillioides to propionyl-CoA-generating carbon sources. Microbiology (2009) 0.79
From attachment to invasion: infection associated genes of Candida albicans. Nihon Ishinkin Gakkai Zasshi (2008) 0.79
Recombinant allergen immunotherapy: clinical evidence of efficacy--a review. Curr Allergy Asthma Rep (2013) 0.78
Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol (2014) 0.77
House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care [ISRCTN63308372]. BMC Fam Pract (2002) 0.77
Hsp21 potentiates antifungal drug tolerance in Candida albicans. PLoS One (2013) 0.77
Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev (2016) 0.76
The nature of suicide: science and the self-destructive animal. Endeavour (2010) 0.76
Gene expression in fungi. IMA Fungus (2011) 0.75
Children must be protected from the tobacco industry's marketing tactics. BMJ (2013) 0.75
The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Int Arch Allergy Immunol (2017) 0.75
Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety. J Asthma (2014) 0.75
Tissue. Lancet (2009) 0.75
A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: The example of the Joint Allergy Academies. Allergy Asthma Proc (2017) 0.75
Sublingual allergen immunotherapy for respiratory allergies: what is new? Expert Rev Clin Immunol (2014) 0.75
Calculable People? Standardising Assessment Guidelines for Alzheimer's Disease in 1980s Britain. Med Hist (2017) 0.75